medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2021, Número 02

<< Anterior Siguiente >>

Ginecol Obstet Mex 2021; 89 (02)


Deficiencia de hierro en mujeres en edad reproductiva. Revisión de la bibliografía

Bernárdez-Zapata FJ

Idioma: Español
Referencias bibliográficas: 51
Paginas: 129-140
Archivo PDF: 231.56 Kb.


RESUMEN

Objetivos: Actualizar los datos de la deficiencia de hierro en México y exponer la evidencia de los desenlaces del tratamiento indicado a pacientes con anemia o deficiencia de hierro.
Metodología: Búsqueda electrónica, en distintas bases de datos, de artículos publicados en español e inglés, entre julio de 2000 y octubre de 2019 con los MeSH: Anemia; Iron deficiency and iron carboxymaltose; Anemia; Deficiencia de hierro; Hierro carboximaltosa.
Resultados: Se localizaron 178 artículos, de los que se seleccionaron 54 por ser congruentes con los objetivos de la revisión. Se excluyeron 128 por problemas de validez metodológica o por falta de correspondencia con los objetivos del estudio. Las fuentes incluidas se enumeran en el apartado de referencias. Con base en los datos de los artículos revisados y la experiencia del autor se emiten recomendaciones concluyentes.
Conclusiones: En México, la frecuencia de deficiencia de hierro y de anemia por deficiencia de hierro es baja, a pesar de que no se dispone de cifras que permitan conocer las tendencias actuales. Las causas de la deficiencia de hierro y de la anemia por deficiencia de hierro son: pérdidas excesivas (hemorragia), pérdidas no recuperadas, incremento de la demanda (embarazo), falta de ingesta y defectos en la absorción. El hierro oral mejor tolerado es el complejo polimaltosa férrico. El hierro carboximaltosa administrado por vía intravenosa es bien tolerado, con tasa de reacciones adversas baja.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. World Health Organization. Global Nutrition Targets 2025: Anaemia policy brief. WHO reference number: WHO/NMH/ NHD/14.4. https://apps.who.int/iris/bitstream/handle/ 10665/148556/WHO_NMH_NHD_14.4_eng.pdf?ua=1.

  2. Coad J, Conlon C. Iron deficiency in women: assessment, causes and consequences. Curr Opin Clin Nutr Metab Care 2011 ;14 (6): 625-34. doi: 10.1097/ MCO.0b013e32834be6fd.

  3. Zimmermann MB, Hurrell RF. Nutritional iron deficiency. Lancet 2007; 11: 370 (9586): 511-20. https://doi. org/10.1016/S0140-6736(07)61235-5.

  4. Organización Panamericana de la Salud. Módulos de principios de epidemiología para el control de enfermedades (MOPECE) Segunda edición revisada. Unidad 2: Salud y enfermedad en la población. 2002. ISBN 92 75 32407 7. https://www.paho.org/bra/index.php?option=com_ docman&view=download&alias=1269-modulos-principios- epidemiologia-para-control-enfermedades-mopeceunidad- 1-presentacion-marco-conceptual-9&category_ slug=informacao-e-analise-saude-096&Itemid=965.

  5. Tussing-Humphreys L, Pusatcioglu C, Nemeth E, Braunschweig C. Rethinking iron regulation and assessment in iron deficiency anemia of chronic disease and obesity: introducing hepcidin. J Acad Nutr Diet. 2012;112(3):391- 400. https://doi.org/10.1016/j.jada.2011.08.038.

  6. World Health Organization. Worldwide prevalence of anaemia 1993-2005: WHO global database on anaemia. Ginebra, Suiza. 2008. World Health Organization. http://whqlibdoc. who.int/publications/2008/9789241596657_eng.pdf.

  7. World Health Organization. Meeting to develop a global consensus on preconception care to reduce maternal and childhood mortality and morbidity. World Health Organization Headquarters, Geneva. 2013. Organización Mundial de la Salud. http://apps.who.int/iris/bitstre am/10665/78067/1/9789241505000_eng.pdf

  8. Pan American Health Organization. “Anemia in Latin America and the Caribbean, 2009: Situation analysis, trends and implications for the public health programming” Washington, DC. PAHO, 2010. https://www.paho.org/hq/ dmdocuments/2011/anemiaLAC.pdf Young MF. Maternal anaemia and risk of mortality: a call for action. Lancet Glob Health 2018; 6 (5): 479-80. https:// doi.org/10.1016/S2214-109X(18)30185-2.

  9. Organización Mundial de la Salud. (2014). Salud para los adolescentes del mundo: una segunda oportunidad en la segunda década: resumen. Organización Mundial de la Salud. https://apps.who.int/iris/handle/10665/141455.

  10. Shamah-Levy T, Villalpando S, Mejía-Rodríguez F, Cuevas-Nasu L1, Gaona-Pineda EB1, Rangel-Baltazar E1 et al. Prevalence of iron, folate, and vitamin B12 deficiencies in 20 to 49 years old women: Ensanut 2012. Salud Publica Mex 2015; 57 (5): 385-93. doi: 10.21149/ spm.v57i5.7618.

  11. Camaschella C, Mentzer WC, Tirnauer JS. Regulation of iron balance. https://www.uptodate.com/contents/regulationof- iron-balance.

  12. Guyton A, Hall J. Tratado de Fisiología. 11ª ed. Elsevier, 2010; 419.

  13. Stanley L, Scherier MD. Causes and diagnosis of iron deficiency anemia in the adult. 2016. www.UpToDate.com.

  14. Beutler E, Waalen J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration? Blood 2006;107(5):1747-1750. doi: 10.1182/ blood-2005-07-3046.

  15. Blanc B, Finch CA, Hallberg L. Nutritional anaemias. Report of a WHO Scientific Group. WHO Tech Rep Ser. 1968;405:1-40.

  16. Montoya Romero JJ, Castelazo Morales E, Valerio Castro E, Velázquez Cornejo G, Nava Muñoz DA, Escárcega Preciado JA et al. Opinión de un grupo de expertos en diagnóstico y tratamiento de la anemia en la mujer embarazada. Ginecol Obstet Mex. 2012;80(09):563-580.

  17. Beard JL. Iron biology in immune function, muscle metabolism and neuronal functioning. J Nutr. 2001;131(2S-2):568- 579. doi: 10.1093/jn/131.2.568S.

  18. Connor JR, Ponnuru P, Wang XS, Patton SM, Allen RP, Earley CJ. Profile of altered brain iron acquisition in restless legs syndrome. Brain 2011;134(4):959-968. doi:10.1093/ brain/awr012.

  19. Khan Y, Tisman G. Pica in iron deficiency: a case series. J Med Case Rep. 2010;4:86. doi: 10.1186/1752-1947-4-86.

  20. Bothwell TH. Iron requirements in pregnancy and strategies to meet them. Am J Clin Nutr. 2000;72(Supl1):257-264. doi: 10.1093/ajcn/72.1.257S.

  21. Sánchez-Muniz FJ, Gesteiro E, Espárrago-Rodilla M, Rodríguez Bernal B, Bastida S. La alimentación de la madre durante el embarazo condiciona el desarrollo pancreático, el estatus hormonal del feto y la concentración de biomarcadores al nacimiento de diabetes mellitus y síndrome metabólico. Nutr Hosp. 2013; 28 (2): 250-74. doi: org/10.3305/nh.2013.28.2.6307.

  22. Breymann C, Gliga F, Bejenariu C, Strizhova N. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynecol Obstet 2008; 101 (1): 67-73. https://doi. org/10.1016/j.ijgo.2007.10.009.

  23. Daru J, Zamora J, Fernández-Félix BM, Vogel J, Oladapo OT, Morisaki N et al. Risk of maternal mortality in women with severe anaemia during pregnancy and post partum: a multilevel analysis. Lancet Glob Health 2018; 6 (5): 548-54. https://doi.org/10.1016/S2214-109X(18)30078-0.

  24. Bunch K, Roberts N, Knight M, Nair M. Systematic review to investigate the safety of induction and augmentation of labour among pregnant women with iron deficiency anaemia. BMJ Open 2018; 8: e021793. http://dx.doi. org/10.1136/bmjopen-2018-021793.

  25. Scholl TO. Maternal iron status: relation to fetal growth, length of gestation and the neonate’s iron endowment. Nutr Rev 2011; 69 (Supl 1): 23-29. https://doi.org/10.1111/ j.1753-4887.2011.00429.x.

  26. Ali MA, Luxton AW, Walker WH. Serum ferritin concentration and bone marrow iron stores: a prospective study. Can Med Assoc J 1978; 118 (8): 945-46.

  27. Omda FA, Nar A, Naggar W, Morsi MA. Comparative study of total dose infusion of iron and intramuscular iron administration in treatment of severe iron deficiency anemia during pregnancy. Egyptian J Hosp Med 2019; 74 (4): 905- 13. 10.12816/ejhm.2019.25558.

  28. Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. Iron deficiency anaemia. Lancet 2016; 387 (10021): 907-16. https://doi.org/10.1016/S0140-6736(15)60865-0.

  29. Api O, Breyman C, Çetiner M, Demir C, Ecder T. Diagnosis and treatment of iron deficiency anemia during pregnancy and the postpartum period: Iron deficiency anemia working group consensus report. Turk J Obstet Gynecol 2015;12(3):173-181. doi:10.4274/tjod.01700.

  30. Geisser P. Safety and Efficacy of iron (III)-hydroxide polymaltose complex / a review of over 25 year’s experience. Arzneimittelforschung 2007; 57 (6A): 439-52. Auerbach M, Macdougall I. The available intravenous iron formulations: History, efficacy, and toxicology. Hemodial Int 2017;21(Supl 1):83-92. https://doi.org/10.1111/ hdi.12560.

  31. Ruiz-Delgado GJ. Deficiencia de hierro. Rev Hematol Mex 2014; 15: 85-86.

  32. Ganzoni AM. Intravenous iron-dextran: therapeutic and experimental possibilities. Schweizerische Medizinische Wochenschrift 1970;100(7):301-303.

  33. Madrazo González Z, García Barrasa A, Rodríguez Lorenzo L, Rafecas Renau A. Intravenous iron. Cir Esp 2009;86(4):196- 203. doi: 10.1016/j.ciresp.2009.05.012.

  34. Peña-Rosas JP, De-Regil LM, Dowswell T, Viteri FE. Daily oral iron supplementation during pregnancy. Cochrane Database Syst Rev. 2012;12:CD004736. https://doi. org/10.1002/14651858.CD004736.pub5.

  35. Haider BA, Olofin I, Wang M, Spiegelman D, Ezzati M, Fawzi WW. Anaemia, prenatal iron use, and risk of adverse pregnancy outcomes: systematic review and meta-analysis. Br Med J 2013; 346: f3443. https://doi.org/10.1136/bmj.f3443

  36. Camaschella C. Iron-deficiency anemia. N Engl J Med 2015; 372 (19): 1832-43. doi: 10.1056/NEJMra1401038.

  37. Pels A, Ganzevoort W. Safety and efficacy of ferric carboxymaltose in anemic pregnant women: a retrospective case control study. Obstet Gynecol Int 2015. https://doi. org/10.1155/2015/728952.

  38. Froessler B, Collingwood J, Hodyl NA, Dekker G. Intravenous ferric carboxymaltose for anaemia in pregnancy. BMC Pregnancy Childbirth 2014; 14: 115. https://doi. org/10.1186/1471-2393-14-115

  39. Froessler B, Gajic T, Dekker G, Hodyl NA. Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy. Arch Gynecol Obstet 2018; 298 (1): 75-82. https://doi.org/10.1007/s00404- 018-4782-9

  40. Scott LJ. Ferric Carboxymaltose: A Review in Iron Deficiency. Drugs 2018 Mar;78(4):479-493. https://doi.org/10.1007/ s40265-018-0885-7.

  41. Qassim A, Mol BW, Grivell RM, Grzeskowiak LE. Safety and efficacy of intravenous iron polymaltose, iron sucrose and ferric carboxymaltose in pregnancy: a systematic review. Aust N Z J Obstet Gynaecol 2018; 58 (1): 22-39. https:// doi.org/10.1111/ajo.12695.

  42. Aporta Rodriguez R, García Montero M, Lorente Aporta JP, Gallego Luque C, Chacón Mayor A, Aragón Ruiz J et al. Retrospective case reports of anemic pregnant women receiving intravenous ferric carboxymaltose: experience from a tertiary hospital in Spain. Obstet Gynecol Int 2016. https://doi.org/10.1155/2016/5060252.

  43. Ambily J, Mahey R, Sharma JB, Bhatla N, Saxena R, Kalaivani M et al. Comparison of ferric carboxymaltose and iron sucrose complex for treatment of iron deficiency anemia in pregnancy- randomised controlled trial. BMC Pregnancy Childbirth 2019; 19 (1): 54 https://doi.org/10.1186/ s12884-019-2200-3.

  44. Khalafallah AA, Hyppa A, Chuang A, Hanna F, Wilson E, Kwok C et al. A prospective randomised controlled trial of a single intravenous infusion of ferric carboxymaltose vs single intravenous iron polymaltose or daily oral ferrous sulphate in the treatment of iron deficiency anaemia in pregnancy. Semin Hematol 2018; 55 (4): 223-34. https:// doi.org/10.1053/j.seminhematol.2018.04.006.

  45. Abdelazim IA, Nusair B, Svetlana S, Zhurabekova G. Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy. Arch Gynecol Obstet 2018;298(6):1231-1232. https://doi. org/10.1007/s00404-018-4943-x

  46. Shim JY, Kim MY, Kim YJ, Lee Y, Lee JJ, Jun JK et al. Efficacy and safety of ferric carboxymaltose versus ferrous sulfate for iron deficiency anemia during pregnancy: subgroup analysis of Korean women. BMC Pregnancy Childbirth 2018; 18 (1): 349. https://doi.org/10.1186/s12884-018- 1817-y.

  47. Gilmartin CE, Hoang T, Cutts BA, Leung L. Retrospective cohort study comparing the adverse reactions and efficacy of intravenous iron polymaltose with ferric carboxymaltose for iron deficiency anemia. Int J Gynaecol Obstet 2018; 141 (3): 315-20. https://doi.org/10.1002/ijgo.12476.

  48. Seid M, Derman R, Banach W, Goldberg C, Rogers R. Ferric carboxymaltose injection in the treatment of iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol 2008; 199: 435. e 1-7. https://doi. org/10.1016/j.ajog.2008.07.046

  49. Damineni SC, Thunga S. IV Ferric carboxymaltose vs oral iron in the treatment of post-partum iron deficiency anaemia. J Clin Diagn Res 2016; 10 (11): QC08-QC10. doi.10.7860/JCDR/2016/19375.8937.

  50. Radhika AG, Sharma AK, Perumal V, et al. Parenteral versus oral iron for treatment of iron deficiency anaemia during pregnancy and post-partum: a systematic review. J Obstet Gynecol India 2019; 69 (1): 13-24. https://doi.org/10.1007/ s13224-018-1191-8.

  51. Muñoz M, Gómez-Ramírez S, Bhandari S. The safety of available treatment options for iron-deficiency anemia. Expert Opin Drug Saf 2018; 17 (2): 149-59. doi: 10.1080/14740338.2018.1400009.




2020     |     www.medigraphic.com